Kymera Therapeutics to Present at Upcoming September Investor Conferences
09/02/2021 - 08:00 AM
WATERTOWN, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will present at two upcoming investor conferences:
Morgan Stanley 19th Annual Global Healthcare Conference: a fireside chat webcast will be available live on Thursday, September 9, 2021 at 1:15 p.m. ET. H.C. Wainwright 23rd Annual Global Investment Conference: an on demand webcast presentation will be available beginning on Monday, September 13, 2021 at 7:00 a.m. ET. Presentation webcasts will be available under "Events and Presentations" in the Investors section of the Company's website at www.kymeratx.com . Archived webcast replays will be available on the website for approximately 30 days.
About Kymera Therapeutics Kymera Therapeutics (Nasdaq: KYMR) is a clinical-stage biopharmaceutical company founded with the mission to discover, develop, and commercialize transformative therapies while leading the evolution of targeted protein degradation, a transformative new approach to address previously intractable disease targets. Kymera’s Pegasus™ platform enables the discovery of novel small molecule degraders designed to harness the body’s natural protein recycling machinery to degrade disease-causing proteins, with a focus on undrugged nodes in validated pathways currently inaccessible with conventional therapeutics. Kymera’s initial programs are IRAK4, IRAKIMiD, and STAT3, each of which addresses high impact targets within the IL-1R/TLR or JAK/STAT pathways, providing the opportunity to treat a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors. Kymera’s goal is to be a fully integrated biopharmaceutical company at the forefront of this new class of protein degrader medicines, with a pipeline of novel degrader medicines targeting disease-causing proteins that were previously intractable.
Founded in 2016, Kymera is headquartered in Watertown, Mass. Kymera has been named a “Fierce 15” biotechnology company by FierceBiotech and has been recognized by the Boston Business Journal as one of Boston’s “Best Places to Work.” For more information about our people, science, and pipeline, please visit www.kymeratx.com or follow us on Twitter or LinkedIn.
Investor Contact: Paul Cox VP, Investor Relations and Communicationspcox@kymeratx.com 917-754-0207
Media Contact: Lissette L. Steele Verge Scientific Communications for Kymera Therapeuticslsteele@vergescientific.com 202-930-4762
KYMR Rankings
#4998 Ranked by Stock Gains
KYMR Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology
Country
US
City
Watertown
About KYMR
kymera therapeutics is pioneering a transformative new approach to treating previously untreatable diseases. we are advancing the field of targeted protein degradation, accessing the body’s innate protein recycling machinery to degrade rather than inhibit dysregulated, disease-causing proteins. powered by a proprietary predictive modeling capability and a game-changing integrated degradation platform with a novel small molecule modality, our company is committed to accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients. learn more at kymeratx.com.